Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an increasingly intertwined human-machine model ...

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of ...

Some proteins embedded in the structure of prions may have antimicrobial activity, according to a study led by scientists at ...

In a little more than a month, 17 big biopharma companies will be subject to U.S. President Donald Trump’s long-promised ...

J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat ...

Bionyra Pharma has emerged with a $165 million oversubscribed series A and a portfolio of three antibodies with extended half ...

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ...

SK Biopharmaceuticals Co. Ltd. is doubling down on AI-powered drug discovery through a new collaboration with Insilico ...

China’s National Medical Products Administration approved Carsgen Therapeutics Holdings Ltd.’s NDA for satricabtagene ...

May was the busiest month of the year so far for U.S. FDA drug approvals, pushing the year-to-date total to 84 approvals and 20 new molecular entities through five months. Globally, drug approvals ...

Memento Medicines Inc. has announced its launch with a $93 million series A financing and the licensing of a lead program for ...

Another day, another about-face by the U.S. FDA on Uniqure NV’s Huntington’s disease gene therapy. But this latest shift ...